Cellect Biotechnology Ltd. (APOP) Analysts See $-0.30 EPS on June, 4

May 17, 2018 - By Robert Reynolds

On June, 4 WallStreet awaited Cellect Biotechnology Ltd. (NASDAQ:APOP)’s earnings release, as reported by Faxor. earnings per share of $-0.30 is 650.00 % down from 2017’s $-0.04 EPS. 87.50 % negative EPS growth is what analysts predict. $-0.16 earnings per share was announced for last quarter. Ticker’s shares touched $7.13 during the last trading session after 0.28% change.Cellect Biotechnology Ltd. has volume of 17,074 shares. Since May 17, 2017 APOP has declined 42.02% and is downtrending. APOP underperformed the S&P500 by 53.57%.

Cellect Biotechnology Ltd., a biotechnology company, focuses on developing technologies for the functional selection of stem cells in the field of regenerative medicine and stem cell therapies in Israel.The company has $46.41 million market cap. It is developing the Apotainer selection kit, a shelf stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies.Currently it has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: